ProPhase Labs, Inc. Dividends Payable, Current
ProPhase Labs, Inc. (PRPH) had Dividends Payable, Current of $2.93 million as of 2018-12-31, per its 10-K filed 2020-03-26.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accrued Liabilities, Current
us-gaap:DividendsPayableCurrent · last filed 2020-03-26
- 2018-12-31: Dividends Payable, Current $2.93M.
| Period end | Dividends Payable, Current |
|---|---|
| 2018-12-31 | $2.93M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |